Is Mounjaro or Wegovy Cheaper in the UK?

What published trial data says about the value of each medicine

Price questions are easier to answer once you know what each medicine delivers clinically. NICE appraised both in detail. Tirzepatide (Mounjaro), a dual GIP and GLP-1 receptor agonist made by Eli Lilly, produced average body-weight reductions of around 20–21% at its highest dose over 72 weeks in SURMOUNT-1, a trial of 2,539 adults with obesity, published in the New England Journal of Medicine. Semaglutide (Wegovy) at 2.4mg produced around 15% average weight loss over 68 weeks in the STEP 1 trial.

The gap narrowed considerably with the MHRA's April 2026 approval of the Wegovy 7.2mg dose, which reported roughly 20.7% average loss in trials — approaching tirzepatide 15mg results. So the clinical difference between the two has shrunk, and which suits a given person is a clinical judgement, not a comparison-table conclusion.

The head-to-head SURMOUNT-5 trial (72 weeks, 751 adults, published in 2025) did find tirzepatide produced greater average weight reduction than semaglutide 2.4mg, as NICE's committee noted in its discussion of indirect comparisons. That evidence is worth knowing, but what it means for you personally requires a prescriber's view of your health history, tolerability and goals, a point the NICE tirzepatide appraisal (TA1026) and the NICE semaglutide appraisal (TA875) both make clear in their eligibility framing.

How UK private prices actually compare, and what the headline figure often leaves out

There is a common assumption that Wegovy is cheaper than Mounjaro across the board. That was broadly true before Lilly's September 2025 list-price revision, but the picture shifted. Reported private market prices since then have ranged roughly £149–£375 per month by dose and provider for both medicines, with higher doses of either costing more, and providers varying in what they bundle in.

The figure worth scrutinising is not the headline monthly price but what sits behind it. Some providers quote the pen price alone. Separate consultation fees, prescription charges, delivery costs and aftercare support can each add to the real figure. A provider quoting a lower monthly number may charge for the initial assessment, charge again for each repeat review, or offer no clinical follow-up between orders. That is not a criticism of any named service; it is just the arithmetic of comparing like with like.

For a fuller breakdown of how the two medicines compare on cost specifically, if you are trying to work out what's cheaper, Mounjaro or Ozempic, including how each sits relative to the licensed alternatives, the dose-by-dose picture is covered in more detail there. And if you are curious about a particular angle (for instance, why Wegovy has historically been priced lower than Mounjaro) that context is worth reading before you choose.

Where nume sits, and why cheapest is the wrong question for a prescription medicine

A named prescriber, not software, reads every consultation at nume. That clinical review happens the same day, and it is the same prescriber model whether you are ordering for the first time or requesting a repeat. One transparent price includes the consultation, the prescription, the medicine, delivery and ongoing aftercare. Current treatment pricing is shown on the weight-loss treatments page.

We do not run discount codes or promotional pricing. For a prescription medicine, a reduced price from an unverified seller is a warning sign, not a bargain. The MHRA has warned publicly about counterfeit weight-loss pens sold online (some containing insulin rather than the stated medicine) and seized roughly 20 million doses of illegally traded GLP-1 medicines with an estimated street value of around £45m in 2025 alone. Any legitimate pharmacy dispensing Mounjaro or Wegovy can be verified on the GPhC register; nume's premises registration is 9012878.

Price is not the right measure for a prescription medicine. What matters is whether the supply chain is licensed, whether a qualified prescriber has assessed you, and whether clinical support is available when you need it. For a broader look at how these two treatments compare beyond cost, the Wegovy vs Mounjaro comparison covers mechanism, evidence and eligibility side by side. If you are weighing up other semaglutide-based options, readers who want to understand whether Ozempic is cheaper than Mounjaro will also find important context there on why Ozempic is not licensed for weight loss in the UK, a distinction that matters before any cost comparison. For a more detailed look at how the two licensed weight-loss medicines stack up on price, the guide to Wegovy vs Mounjaro cost breaks down what you can expect to pay at each dose.

The right starting point is a free clinical consultation. Check your eligibility and a prescriber will assess which treatment, if either, is appropriate for you.